TITLE

Biotech's Plan B: Merge, Merge, Merge

AUTHOR(S)
Santini, Laura
PUB. DATE
January 2004
SOURCE
Investment Dealers' Digest;1/5/2004, Vol. 70 Issue 1, p13
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on extremely favorable conditions for mergers and acquisitions in the biotechnology industry at the start of 2004. Conditions cited by investment bankers; Poor share prices of initial public offerings of the final quarter of 2003; Improved valuations among buyers and sellers; Access to capital in the form of debt and secondary stock offerings.
ACCESSION #
11857968

 

Related Articles

  • Biotech Charts Technology Recovery. Thurston, Charles W. // Global Finance;Sep2000, Vol. 14 Issue 9, p84 

    Discusses the recovery of biotechnology's initial public offering market as of September 2000. Remarks from Ronald B. Gies, vice president of corporate research at Stone & Youngberg; Rise in venture capital for biotechnology; Factors that lead to mergers and acquisitions in biotechnology industry.

  • Why Techies Shun IPOs. Whiddon, Robert // Traders Magazine;Mar2000, Vol. 13 Issue 164, p24 

    Discusses the strategy used by technology based companies in going public. Examples of companies favoring mergers and offers of acquisition over initial public offerings (IPO); Benefits of IPO; Information on methods of company valuation.

  • Reverse Mergers an Option for Firms Deemed Acquisition Risks. Boggs, Jennifer // BioWorld Today;9/29/2008, Vol. 19 Issue 189, p1 

    The article reveals how reverse mergers have become an ideal option for biotech firms to access capital and public markets. At a panel session at the Georgia Life Sciences Summit meeting in Atlanta, Bruce Robertson, managing director at H.I.G. Ventures, noted that firms that can attract the...

  • Bankers Say Selective Windows, Low Prices Will Continue in 2008. Morrison, Trista // BioWorld Today;1/3/2008, Vol. 19 Issue 2, p1 

    The article predicts a selective opening and closing of the window for biotech initial public offerings (IPO) in 2008. According to Bank of America investment banker Mark Dempster, there is a continued trend toward pricing below or at the low end of companies' original filing ranges. Genoptix...

  • Reverse Merger Interest Dims As IPO Window Creaks Open. Boggs, Jennifer // BioWorld Insight;2/28/2011, Vol. 19 Issue 9, p1 

    The article focuses on the switch from reverse mergers to initial public offering (IPO) for biotechnology companies to raise cash. It mentions that reverse merger serves an exit trend in companies that are unsuccessful in their IPO bids. According to analyst Jason Napodano of Zack's Investment...

  • Athersys Goes Public Through Reverse Merger, Raises $65M. Boggs, Jennifer // BioWorld Today;6/12/2007, Vol. 18 Issue 113, p3 

    The article reports on the completion of a reverse merger with public shell company BTHC VI Inc. to gain a listing on the Over-The-Counter Bulletin Board. Athersys Inc. has raised $65 million in a private placement to fund ongoing development of its program aimed at obesity and a stem cell...

  • Is M&A The New IPO? Only For Some, Panel Says. Boggs, Jennifer // BioWorld Today;6/20/2007, Vol. 18 Issue 119, p1 

    The article provides information on the issues discussed at Venture Forum East meeting in Montreal, Quebec in 2007. According to panelists, merger and acquisitions are replacing initial public offerings (IPOs) as the preferred exit strategy for shareholders of small and midsize biotech...

  • Earlier stage biotechs attract partners. Ratner, Mark // Nature Biotechnology;May2005, Vol. 23 Issue 5, p509 

    The article reports on certain favorable financing alternatives available to most biotech companies and their investors regarding going public. A spate of recent acquisitions and a continuation of early-stage deal making signify that there are still appealing ways for many companies to sustain...

  • Biotech Posts Strong Gains. Burrill, G. Steven // BioPharm International;Jul2011, Vol. 24 Issue 7, p20 

    The article discusses the condition of biotech industries in the U.S. It states that the industry's collective market cap has exceeded 400 billion dollars for the first time since February 2009 which is attributed to mergers and acquisitions. It details several mergers and acquisitions including...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics